Biomarker study of a multicentre, open-label, randomized Phase III Study of Atezolizumab with Platinum-Pemetrexed with or without Bevacizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer WJOG11218L/APPLE (APPLE Biomarker study) (WJOG11218LTR)
Not Applicable
- Conditions
- advanced non-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000037326
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Subjects who do not agree by consent forms to attend this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method